STOCK TITAN

[8-K] Jazz Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

N2OFF, Inc. (Nasdaq: NITO) has called a 2025 special meeting to seek shareholder approval for four key proposals.

  • Acquisition: N2OFF will buy 100% of Israeli oncology start-up MitoCareX Bio Ltd. by issuing new NITO shares equal to ≈40% of post-close fully diluted shares plus up to another 25% in milestone stock, $700k cash and up to $1.6 m of future-financing proceeds. MitoCareX founders will also receive 5% RSUs and board control of the subsidiary.
  • Reverse split: Board authority to effect a 1-for-2 to 1-for-150 reverse split within 12 months.
  • Warrants: Approval to issue 1,850,000 common shares on exercise of a warrant held by L.I.A. Pure Capital Ltd.
  • Adjournment: Standard authority if more time is needed to solicit votes.

The board unanimously recommends voting FOR all items. If approved, existing holders face substantial dilution, potential additional issuance through milestones and warrants, and the possibility of a large reverse split to maintain Nasdaq compliance. The deal adds an early-stage oncology platform but exposes N2OFF to R&D funding obligations and integration risks. Two N2OFF directors also serve on MitoCareX seller SciSparc’s board, creating related-party considerations.

N2OFF, Inc. (Nasdaq: NITO) ha convocato un'assemblea speciale nel 2025 per ottenere l'approvazione degli azionisti su quattro proposte chiave.

  • Acquisizione: N2OFF acquisirà il 100% della start-up oncologica israeliana MitoCareX Bio Ltd. emettendo nuove azioni NITO pari a circa il 40% delle azioni totalmente diluite dopo la chiusura, più fino al 25% aggiuntivo in azioni legate al raggiungimento di milestone, 700.000 dollari in contanti e fino a 1,6 milioni di dollari provenienti da futuri finanziamenti. I fondatori di MitoCareX riceveranno inoltre il 5% in RSU e il controllo del consiglio della controllata.
  • Reverse split: Autorizzazione al consiglio per effettuare un raggruppamento azionario da 1 per 2 fino a 1 per 150 entro 12 mesi.
  • Warrant: Approvazione per emettere 1.850.000 azioni ordinarie in seguito all'esercizio di un warrant detenuto da L.I.A. Pure Capital Ltd.
  • Rinvio: Autorizzazione standard nel caso sia necessario più tempo per raccogliere i voti.

Il consiglio raccomanda all'unanimità di votare SI su tutti i punti. Se approvato, gli azionisti attuali subiranno una sostanziale diluizione, possibili ulteriori emissioni tramite milestone e warrant, e la possibilità di un ampio raggruppamento azionario per mantenere la conformità al Nasdaq. L'accordo aggiunge una piattaforma oncologica in fase iniziale ma espone N2OFF a obblighi di finanziamento per R&S e rischi di integrazione. Due direttori di N2OFF siedono anche nel consiglio di SciSparc, venditore di MitoCareX, creando considerazioni di parti correlate.

N2OFF, Inc. (Nasdaq: NITO) ha convocado una reunión especial en 2025 para solicitar la aprobación de los accionistas sobre cuatro propuestas clave.

  • Adquisición: N2OFF comprará el 100% de la start-up oncológica israelí MitoCareX Bio Ltd. mediante la emisión de nuevas acciones NITO equivalentes a aproximadamente el 40% de las acciones totalmente diluidas después del cierre, más hasta un 25% adicional en acciones condicionadas a hitos, 700,000 dólares en efectivo y hasta 1.6 millones de dólares de futuros ingresos por financiamiento. Los fundadores de MitoCareX también recibirán un 5% en RSU y el control del consejo de la subsidiaria.
  • Split inverso: Autoridad para la junta para realizar una división inversa de acciones de 1 por 2 a 1 por 150 dentro de 12 meses.
  • Warrants: Aprobación para emitir 1,850,000 acciones ordinarias tras el ejercicio de un warrant en poder de L.I.A. Pure Capital Ltd.
  • Aplazamiento: Autoridad estándar si se necesita más tiempo para solicitar votos.

La junta recomienda por unanimidad votar A FAVOR de todos los puntos. Si se aprueba, los accionistas actuales enfrentarán una dilución sustancial, potencial emisión adicional mediante hitos y warrants, y la posibilidad de una gran división inversa para mantener el cumplimiento con Nasdaq. El acuerdo añade una plataforma oncológica en etapa temprana pero expone a N2OFF a obligaciones de financiamiento de I+D y riesgos de integración. Dos directores de N2OFF también forman parte del consejo de SciSparc, vendedor de MitoCareX, lo que genera consideraciones de partes relacionadas.

N2OFF, Inc. (나스닥: NITO)는 2025년 특별 주주총회를 소집하여 네 가지 주요 안건에 대한 주주 승인을 요청합니다.

  • 인수: N2OFF는 이스라엘의 초기 암 치료 스타트업 MitoCareX Bio Ltd.의 100% 지분을 인수하며, 이 과정에서 거래 종료 후 완전 희석 주식의 약 40%에 해당하는 신규 NITO 주식을 발행하고, 추가로 최대 25%의 마일스톤 주식, 70만 달러 현금, 그리고 최대 160만 달러의 미래 자금 조달 수익을 지급합니다. MitoCareX 창업자들은 5%의 RSU와 자회사의 이사회 통제권도 받게 됩니다.
  • 역병합: 이사회가 12개월 이내에 1대 2에서 1대 150까지의 역병합을 시행할 권한을 부여받습니다.
  • 워런트: L.I.A. Pure Capital Ltd.가 보유한 워런트 행사 시 1,850,000 보통주 발행 승인을 요청합니다.
  • 연기: 투표를 더 많이 확보하기 위해 시간이 더 필요할 경우 표준 연기 권한입니다.

이사회는 모든 안건에 대해 만장일치로 찬성 투표를 권고합니다. 승인될 경우 기존 주주들은 상당한 희석 효과와 마일스톤 및 워런트를 통한 추가 발행 가능성, 그리고 나스닥 규정 준수를 위한 대규모 역병합 가능성에 직면하게 됩니다. 이번 거래는 초기 단계의 암 치료 플랫폼을 추가하지만 N2OFF에 연구개발 자금 조달 의무와 통합 위험을 안겨줍니다. 또한 N2OFF 이사 두 명이 MitoCareX 매도자인 SciSparc 이사회에도 참여하고 있어 이해관계 관련 문제가 발생합니다.

N2OFF, Inc. (Nasdaq : NITO) a convoqué une assemblée générale extraordinaire en 2025 pour obtenir l'approbation des actionnaires sur quatre propositions clés.

  • Acquisition : N2OFF achètera 100 % de la start-up israélienne en oncologie MitoCareX Bio Ltd. en émettant de nouvelles actions NITO représentant environ 40 % des actions entièrement diluées après clôture, plus jusqu'à 25 % supplémentaires en actions liées à des jalons, 700 000 $ en espèces et jusqu'à 1,6 million de dollars provenant de financements futurs. Les fondateurs de MitoCareX recevront également 5 % de RSU et le contrôle du conseil d'administration de la filiale.
  • Regroupement d’actions : Pouvoir au conseil d'effectuer un regroupement d’actions de 1 pour 2 à 1 pour 150 dans les 12 mois.
  • Bons de souscription : Approbation pour émettre 1 850 000 actions ordinaires à l’exercice d’un bon de souscription détenu par L.I.A. Pure Capital Ltd.
  • Ajournement : Pouvoir standard si plus de temps est nécessaire pour solliciter les votes.

Le conseil recommande à l’unanimité de voter POUR tous les points. En cas d’approbation, les actionnaires actuels subiront une dilution importante, des émissions potentielles supplémentaires via des jalons et des bons, ainsi que la possibilité d’un important regroupement d’actions pour maintenir la conformité au Nasdaq. L’accord ajoute une plateforme oncologique en phase précoce mais expose N2OFF à des obligations de financement en R&D et à des risques d’intégration. Deux administrateurs de N2OFF siègent également au conseil de SciSparc, vendeur de MitoCareX, ce qui soulève des questions de conflits d’intérêts.

N2OFF, Inc. (Nasdaq: NITO) hat für 2025 eine außerordentliche Hauptversammlung einberufen, um die Zustimmung der Aktionäre zu vier wichtigen Vorschlägen einzuholen.

  • Akquisition: N2OFF wird 100 % des israelischen Onkologie-Start-ups MitoCareX Bio Ltd. erwerben, indem neue NITO-Aktien ausgegeben werden, die ca. 40 % der nach Abschluss voll verwässerten Aktien entsprechen, plus bis zu 25 % weitere Aktien bei Erreichen von Meilensteinen, 700.000 USD in bar und bis zu 1,6 Mio. USD aus zukünftigen Finanzierungen. Die Gründer von MitoCareX erhalten zudem 5 % RSUs und die Kontrolle über den Vorstand der Tochtergesellschaft.
  • Aktienzusammenlegung: Der Vorstand erhält die Befugnis, innerhalb von 12 Monaten eine Reverse Split von 1:2 bis 1:150 durchzuführen.
  • Warrants: Genehmigung zur Ausgabe von 1.850.000 Stammaktien bei Ausübung eines Warrants, der von L.I.A. Pure Capital Ltd. gehalten wird.
  • Vertagung: Standardbefugnis, falls mehr Zeit zur Einholung der Stimmen benötigt wird.

Der Vorstand empfiehlt einstimmig, allen Punkten ZU ZUSTIMMEN. Bei Genehmigung sehen sich bestehende Aktionäre einer erheblichen Verwässerung, möglichen zusätzlichen Ausgaben durch Meilensteine und Warrants sowie der Möglichkeit einer großen Aktienzusammenlegung gegenüber, um die Nasdaq-Compliance zu wahren. Der Deal erweitert die frühe Onkologie-Plattform, bringt jedoch Verpflichtungen zur F&E-Finanzierung und Integrationsrisiken mit sich. Zwei N2OFF-Direktoren sind auch im Vorstand von SciSparc, dem Verkäufer von MitoCareX, was Interessenkonflikte mit sich bringt.

Positive
  • Diversification into oncology drug discovery via MITOLINE™ platform
  • Potential technological synergies and strengthened management team from MitoCareX
  • Milestone structure ties part of consideration to future performance
Negative
  • Immediate dilution of ≈40% at closing, rising to ≈65% if milestones and warrants are met
  • Large reverse split (up to 1-for-150) signals Nasdaq compliance pressure
  • Ongoing cash obligation to fund MitoCareX R&D beyond initial $1 m
  • Early-stage target risk: no products, limited operating history, accumulated deficit
  • Related-party relationships could create perceived conflicts of interest

Insights

TL;DR: Highly dilutive biotech acquisition; strategic upside but significant execution and funding risk.

The transaction transforms N2OFF from its current scope into an early-stage oncology player, issuing up to 65% of post-close equity (40% at close + 25% milestones) and committing at least $1 m in fresh cash plus ongoing R&D support. While the MITOLINE™ platform could broaden the company’s technology stack, MitoCareX has no revenue, $2.1 m accumulated deficit and funding runway only into Q4-25, meaning N2OFF must raise capital soon—now under more dilutive terms. The optional 1-for-150 reverse split signals concern over Nasdaq bid-price compliance. Shareholders should weigh long-term optionality against near-term dilution, integration complexity and biotech execution risk.

TL;DR: Governance red flags offset by clear disclosure and audit-committee approval.

Two N2OFF directors sit on the board of seller SciSparc and the target’s CSO is related to a N2OFF lender, creating conflicts. Management mitigated this via audit-committee review and full proxy disclosure, but minority shareholders still bear dilution and financing obligations. The capped indemnities, two-year rep & warranty survival and milestone-based earn-outs are standard, yet the 30% cut of future financings to sellers until $1.6 m is paid is unusual and could burden capital raises. Overall impact is neutral: governance process appears adequate, but structural terms favor sellers.

N2OFF, Inc. (Nasdaq: NITO) ha convocato un'assemblea speciale nel 2025 per ottenere l'approvazione degli azionisti su quattro proposte chiave.

  • Acquisizione: N2OFF acquisirà il 100% della start-up oncologica israeliana MitoCareX Bio Ltd. emettendo nuove azioni NITO pari a circa il 40% delle azioni totalmente diluite dopo la chiusura, più fino al 25% aggiuntivo in azioni legate al raggiungimento di milestone, 700.000 dollari in contanti e fino a 1,6 milioni di dollari provenienti da futuri finanziamenti. I fondatori di MitoCareX riceveranno inoltre il 5% in RSU e il controllo del consiglio della controllata.
  • Reverse split: Autorizzazione al consiglio per effettuare un raggruppamento azionario da 1 per 2 fino a 1 per 150 entro 12 mesi.
  • Warrant: Approvazione per emettere 1.850.000 azioni ordinarie in seguito all'esercizio di un warrant detenuto da L.I.A. Pure Capital Ltd.
  • Rinvio: Autorizzazione standard nel caso sia necessario più tempo per raccogliere i voti.

Il consiglio raccomanda all'unanimità di votare SI su tutti i punti. Se approvato, gli azionisti attuali subiranno una sostanziale diluizione, possibili ulteriori emissioni tramite milestone e warrant, e la possibilità di un ampio raggruppamento azionario per mantenere la conformità al Nasdaq. L'accordo aggiunge una piattaforma oncologica in fase iniziale ma espone N2OFF a obblighi di finanziamento per R&S e rischi di integrazione. Due direttori di N2OFF siedono anche nel consiglio di SciSparc, venditore di MitoCareX, creando considerazioni di parti correlate.

N2OFF, Inc. (Nasdaq: NITO) ha convocado una reunión especial en 2025 para solicitar la aprobación de los accionistas sobre cuatro propuestas clave.

  • Adquisición: N2OFF comprará el 100% de la start-up oncológica israelí MitoCareX Bio Ltd. mediante la emisión de nuevas acciones NITO equivalentes a aproximadamente el 40% de las acciones totalmente diluidas después del cierre, más hasta un 25% adicional en acciones condicionadas a hitos, 700,000 dólares en efectivo y hasta 1.6 millones de dólares de futuros ingresos por financiamiento. Los fundadores de MitoCareX también recibirán un 5% en RSU y el control del consejo de la subsidiaria.
  • Split inverso: Autoridad para la junta para realizar una división inversa de acciones de 1 por 2 a 1 por 150 dentro de 12 meses.
  • Warrants: Aprobación para emitir 1,850,000 acciones ordinarias tras el ejercicio de un warrant en poder de L.I.A. Pure Capital Ltd.
  • Aplazamiento: Autoridad estándar si se necesita más tiempo para solicitar votos.

La junta recomienda por unanimidad votar A FAVOR de todos los puntos. Si se aprueba, los accionistas actuales enfrentarán una dilución sustancial, potencial emisión adicional mediante hitos y warrants, y la posibilidad de una gran división inversa para mantener el cumplimiento con Nasdaq. El acuerdo añade una plataforma oncológica en etapa temprana pero expone a N2OFF a obligaciones de financiamiento de I+D y riesgos de integración. Dos directores de N2OFF también forman parte del consejo de SciSparc, vendedor de MitoCareX, lo que genera consideraciones de partes relacionadas.

N2OFF, Inc. (나스닥: NITO)는 2025년 특별 주주총회를 소집하여 네 가지 주요 안건에 대한 주주 승인을 요청합니다.

  • 인수: N2OFF는 이스라엘의 초기 암 치료 스타트업 MitoCareX Bio Ltd.의 100% 지분을 인수하며, 이 과정에서 거래 종료 후 완전 희석 주식의 약 40%에 해당하는 신규 NITO 주식을 발행하고, 추가로 최대 25%의 마일스톤 주식, 70만 달러 현금, 그리고 최대 160만 달러의 미래 자금 조달 수익을 지급합니다. MitoCareX 창업자들은 5%의 RSU와 자회사의 이사회 통제권도 받게 됩니다.
  • 역병합: 이사회가 12개월 이내에 1대 2에서 1대 150까지의 역병합을 시행할 권한을 부여받습니다.
  • 워런트: L.I.A. Pure Capital Ltd.가 보유한 워런트 행사 시 1,850,000 보통주 발행 승인을 요청합니다.
  • 연기: 투표를 더 많이 확보하기 위해 시간이 더 필요할 경우 표준 연기 권한입니다.

이사회는 모든 안건에 대해 만장일치로 찬성 투표를 권고합니다. 승인될 경우 기존 주주들은 상당한 희석 효과와 마일스톤 및 워런트를 통한 추가 발행 가능성, 그리고 나스닥 규정 준수를 위한 대규모 역병합 가능성에 직면하게 됩니다. 이번 거래는 초기 단계의 암 치료 플랫폼을 추가하지만 N2OFF에 연구개발 자금 조달 의무와 통합 위험을 안겨줍니다. 또한 N2OFF 이사 두 명이 MitoCareX 매도자인 SciSparc 이사회에도 참여하고 있어 이해관계 관련 문제가 발생합니다.

N2OFF, Inc. (Nasdaq : NITO) a convoqué une assemblée générale extraordinaire en 2025 pour obtenir l'approbation des actionnaires sur quatre propositions clés.

  • Acquisition : N2OFF achètera 100 % de la start-up israélienne en oncologie MitoCareX Bio Ltd. en émettant de nouvelles actions NITO représentant environ 40 % des actions entièrement diluées après clôture, plus jusqu'à 25 % supplémentaires en actions liées à des jalons, 700 000 $ en espèces et jusqu'à 1,6 million de dollars provenant de financements futurs. Les fondateurs de MitoCareX recevront également 5 % de RSU et le contrôle du conseil d'administration de la filiale.
  • Regroupement d’actions : Pouvoir au conseil d'effectuer un regroupement d’actions de 1 pour 2 à 1 pour 150 dans les 12 mois.
  • Bons de souscription : Approbation pour émettre 1 850 000 actions ordinaires à l’exercice d’un bon de souscription détenu par L.I.A. Pure Capital Ltd.
  • Ajournement : Pouvoir standard si plus de temps est nécessaire pour solliciter les votes.

Le conseil recommande à l’unanimité de voter POUR tous les points. En cas d’approbation, les actionnaires actuels subiront une dilution importante, des émissions potentielles supplémentaires via des jalons et des bons, ainsi que la possibilité d’un important regroupement d’actions pour maintenir la conformité au Nasdaq. L’accord ajoute une plateforme oncologique en phase précoce mais expose N2OFF à des obligations de financement en R&D et à des risques d’intégration. Deux administrateurs de N2OFF siègent également au conseil de SciSparc, vendeur de MitoCareX, ce qui soulève des questions de conflits d’intérêts.

N2OFF, Inc. (Nasdaq: NITO) hat für 2025 eine außerordentliche Hauptversammlung einberufen, um die Zustimmung der Aktionäre zu vier wichtigen Vorschlägen einzuholen.

  • Akquisition: N2OFF wird 100 % des israelischen Onkologie-Start-ups MitoCareX Bio Ltd. erwerben, indem neue NITO-Aktien ausgegeben werden, die ca. 40 % der nach Abschluss voll verwässerten Aktien entsprechen, plus bis zu 25 % weitere Aktien bei Erreichen von Meilensteinen, 700.000 USD in bar und bis zu 1,6 Mio. USD aus zukünftigen Finanzierungen. Die Gründer von MitoCareX erhalten zudem 5 % RSUs und die Kontrolle über den Vorstand der Tochtergesellschaft.
  • Aktienzusammenlegung: Der Vorstand erhält die Befugnis, innerhalb von 12 Monaten eine Reverse Split von 1:2 bis 1:150 durchzuführen.
  • Warrants: Genehmigung zur Ausgabe von 1.850.000 Stammaktien bei Ausübung eines Warrants, der von L.I.A. Pure Capital Ltd. gehalten wird.
  • Vertagung: Standardbefugnis, falls mehr Zeit zur Einholung der Stimmen benötigt wird.

Der Vorstand empfiehlt einstimmig, allen Punkten ZU ZUSTIMMEN. Bei Genehmigung sehen sich bestehende Aktionäre einer erheblichen Verwässerung, möglichen zusätzlichen Ausgaben durch Meilensteine und Warrants sowie der Möglichkeit einer großen Aktienzusammenlegung gegenüber, um die Nasdaq-Compliance zu wahren. Der Deal erweitert die frühe Onkologie-Plattform, bringt jedoch Verpflichtungen zur F&E-Finanzierung und Integrationsrisiken mit sich. Zwei N2OFF-Direktoren sind auch im Vorstand von SciSparc, dem Verkäufer von MitoCareX, was Interessenkonflikte mit sich bringt.

0001232524falseJazz Pharmaceuticals plc00012325242025-07-242025-07-24

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
  
FORM 8-K
  
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 24, 2025
Date of Report (Date of earliest event reported)
 
 
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
 
     
Ireland 001-33500 98-1032470
(State or Other Jurisdiction
of Incorporation)
(Commission
File No.)
(IRS Employer
Identification No.)
Fifth Floor, Waterloo Exchange,
Waterloo Road, Dublin 4, Ireland D04 E5W7
(Address of principal executive offices, including zip code)

011-353-1-634-7800
(Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
JAZZ
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.07. Submission of Matters to a Vote of Security Holders.
Results of Matters Presented at the 2025 Annual General Meeting of Shareholders
On July 24, 2025, we held our 2025 annual general meeting of shareholders, or the Annual Meeting, at our corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. At the Annual Meeting, our shareholders voted on four proposals, each of which is described in more detail in our definitive proxy statement on Schedule 14A as filed with the SEC on June 6, 2025, or the Proxy Statement. The results of the matters presented at the Annual Meeting, based on the presence in person or by proxy of holders of 55,808,012 of the 60,511,021 ordinary shares entitled to vote, are described below.
Proposal 1
Proposal 1 was to elect by separate resolutions each of the four nominees for director named below to hold office until our 2028 annual general meeting of shareholders. Each of the four nominees for director was elected as follows:
Director NomineesForAgainstAbstainBroker Non-Votes
Jennifer E. Cook49,838,7611,472,37331,1824,465,696
Patrick G. Enright49,122,8082,186,96332,5454,465,696
Seamus Mulligan49,488,3551,821,94232,0194,465,696
Norbert G. Riedel, Ph.D.46,521,5834,787,90332,8304,465,696
Proposal 2
Proposal 2 was to ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, our board of directors, acting through the audit committee, to determine the auditors’ remuneration. This proposal was approved as follows:
ForAgainstAbstainBroker Non-Votes
54,773,976996,90137,135
Proposal 3
Proposal 3 was to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. This proposal was approved as follows:
ForAgainstAbstainBroker Non-Votes
48,261,1492,887,574193,5934,465,696
Proposal 4
Proposal 4 was to grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. This proposal was approved as follows:
ForAgainstAbstainBroker Non-Votes
53,607,2442,159,20141,567






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
 
By:/s/ Neena Patil
Name:Neena Patil
Title:Executive Vice President and Chief Legal Officer
Date: July 25, 2025




FAQ

What is N2OFF (NITO) asking shareholders to approve?

Four proposals: the MitoCareX acquisition, a 1-for-2 to 1-for-150 reverse split, 1.85 m warrant shares, and potential meeting adjournment.

How much dilution will current NITO shareholders face?

≈40% at closing and up to ≈25% more on milestone achievement, plus 1.85 m warrant shares.

Why is a reverse stock split proposed?

To give the board flexibility to cure potential Nasdaq bid-price deficiencies and manage share count after dilution.

How is MitoCareX being valued in the deal?

Through equity equal to 40% of NITO plus cash and earn-outs; no cash revenue metrics were disclosed.

When will the special meeting take place?

At 4:00 p.m. Israel time (9:00 a.m. EDT) on a date in 2025 to be specified in the final proxy materials.

What funding commitments has N2OFF made to MitoCareX?

An initial $1 m (less prior loans) at closing and additional R&D funding subject to board approval and resources.
Jazz Pharmaceuticals Plc

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Latest SEC Filings

JAZZ Stock Data

7.10B
58.66M
3.09%
99.91%
7.19%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN